Skip to main content
Premium Trial:

Request an Annual Quote

NovellusDx Inks Japan Distribution Deal for Cancer Treatment Response Assay

NEW YORK (GenomeWeb) — NovellusDx said today that it has signed a deal with Primetech for the distribution of its functional annotation for cancer treatment (FACT) assay in Japan.

The next-generation sequencing-based FACT assay is designed to test the functional effects of variants of unknown significance in reponse to various cancer treatments to predict clinical results.

Under the terms of the deal, Tokyo-based Primetech will be the exclusive dealer for the assay for the preclinical market in Japan, providing all related sales, marketing, research, and technical support in the region.

Additional terms were not disclosed.

Earlier this year, Jerusalem-based NovellusDx partnered with Centre Léon-Bérard to evaluate the accuracy of the FACT assay in predicting treatment responses in cancer patients. The company also recently raised $6 million in equity financing.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.